CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
CSL Enters Licensing Agreement with Arcturus Therapeutics : Today, CSL Limited reports that its subsidiary, CSL Seqirus, has collaborated and licenced its late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology to Arcturus Therapeutics Holdings Inc (or “Arcturus Therapeutics”). Future mRNA vaccines…